Updated results of the phase III KEYNOTE-048 trial comparing pembrolizumab as monotherapy and in combination with platinum chemotherapy and fluorouracil with standard-of-care chemotherapy support the use of the PD-1 inhibitor in the frontline for patients with recurrent or metastatic head and neck squamous cell carcinoma, according to Danny Rischin, MD, who presented the results of the final analysis at the 2019 American Society of Clinical Oncology Annual Meeting.